| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. | Director | Common Stock | 25.7K | $5.87K | $0.23 | Jan 1, 2025 | Direct |
| Zymeworks Inc. | Chief Scientific Officer | Stock Option (Right to Buy) | 77.6K | Aug 31, 2021 | Direct | ||
| Zymeworks Inc. | Chief Scientific Officer | Common Shares | 36.4K | Jan 7, 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| BCLI | BRAINSTORM CELL THERAPEUTICS INC. | Jan 1, 2025 | 1 | $0 | 4 | Jan 3, 2025 | Director |
| BCLI | BRAINSTORM CELL THERAPEUTICS INC. | Feb 1, 2022 | 1 | $0 | 4 | Feb 3, 2022 | Director |
| ZYME | Zymeworks Inc. | Jan 7, 2022 | 1 | $1.03K | 4 | Jan 7, 2022 | Chief Scientific Officer |
| BCLI | BRAINSTORM CELL THERAPEUTICS INC. | Dec 15, 2021 | 1 | $0 | 4 | Dec 17, 2021 | Director |
| BCLI | BRAINSTORM CELL THERAPEUTICS INC. | Dec 10, 2021 | 2 | $0 | 4 | Dec 10, 2021 | Director |
| ZYME | Zymeworks Inc. | Aug 31, 2021 | 2 | $73.5K | 4 | Sep 2, 2021 | Chief Scientific Officer |
| ZYME | Zymeworks Inc. | Jul 6, 2021 | 1 | $13.4K | 4 | Jul 8, 2021 | Chief Scientific Officer |